National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Avatrombopag (Doptelet®). HTA ID: 20006

Avatrombopag is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.


NCPE Assessment Process Complete
Rapid review commissioned 11/02/2020
Rapid review completed 02/04/2020
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that avatrombopag be considered for reimbursement*.


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement; September 2020